



ReNerve^{LTD}

ASX:RNV

Transforming Nerve Repair Through Science

ReNerve Company presentation
Annual General Meeting | October 2026

Important Notice & Disclaimer

Nature of Document: This presentation has been prepared and issued by ReNerve Ltd (Company) to provide general information about the Company. The information in this document is in summary form and should not be relied upon as a complete and accurate representation of any matters that a reader should consider in evaluating the Company. While management has taken every effort to ensure the accuracy of the material in this presentation, the Company have not verified the accuracy or completeness of the material contained in this presentation.

Not an offer: this presentation should not be distributed, transmitted, or viewed by any person in any jurisdiction where the distribution, transmission or viewing of this document would be unlawful under the securities or other laws of that or any other jurisdiction.

Not financial product advice: You should not act and should refrain from acting in reliance on this presentation. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This presentation does not take into account the individual investment objectives, financial situation and particular needs of potential investors. Before making a decision to invest in the Company at any time, you should conduct, with the assistance of your broker or other financial or professional adviser, your own investigation in light of your particular investment needs, objectives and financial circumstances and perform your own analysis of the Company before making any investment decision.

Forward looking statements: This presentation contains forward-looking information about the Company and its operations. In certain cases, forward-looking information may be identified by such terms as "anticipates", "believes", "should", "could", "estimates", "target", "likely", "plan", "expects", "may", "intend", "shall", "will", or "would". These statements are based on information currently available to the Company and the Company provides no assurance that actual results will meet management's expectations. Forward-looking statements are subject to risk factors associated with the Company's business, many of which are beyond the control of the Company. It is believed that the expectations reflected in these statements are reasonable but they may be affected by a variety of variables and changes in underlying assumptions which could cause actual results or trends to differ materially from those expressed or implied in such statements. There can be no assurance that actual outcomes will not differ materially from these statements.

Disclaimer: No representation or warranty, express or implied, is made by the Company that the material contained in this presentation will be achieved or proved correct. Except for statutory liability which cannot be excluded, the Company, its directors, officers, and employees expressly disclaim any responsibility for the accuracy, fairness, sufficiency or completeness of the material contained in this presentation and excludes all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any effort or omission therefrom. The Company will not update or keep current the information contained in this presentation or to correct any inaccuracy or omission which may become apparent, or to furnish any person with any further information. Any opinions expressed in the presentation are subject to change without notice. Additional information can be found on the Company's website (www.renerve.com.au).

Speculative nature of investment: Any potential investor should be aware that subscribing for Shares involves various risks. The Shares to be issued pursuant to the Prospectus lodged with ASIC by ReNerve Ltd carry no guarantee with respect to the payment of dividends, returns of capital or the market value of those Shares. An investment in Shares of the Company should therefore be considered very speculative.

ReNerve Ltd ABN 23 614 848 216

Executive Summary



Development of Novel Nerve Repair & Regeneration Products



ReNerve is developing a comprehensive portfolio of products for the nerve repair and regeneration markets and related surgical procedures, with clearly defined commercial position and demand.


Expanding Product Portfolio



3 product ranges in the US market with more coming in 2026 to 2029

Robust R&D pipeline grounded in rigorous science, advancing next-generation nerve repair solutions to deliver better patient outcomes

Strong Sales & Distribution Presence



ReNerve has established logistics, warehouse and invoicing infrastructure with a strong focus on building a sales distribution network for all products in the US.

Global Expansion & Commercialisation



Successful ongoing expansion within the first year of ASX listing into Ex-US markets in Asia, India, The Middle East, and The Americas.

Clinical & Professional Validation



Improved patient outcomes for post-surgical measures of pain and surgery satisfaction, as well as proven ease of use for surgeons.

Company Portfolio



Quarter highlights

Annual revenue

up **88%**

Revenue up **>50%**
Compared to the previous qtr

30th of June

Cash of


\$1.48M


Signed a

\$5M funding

facility with Riverfort in early July

ReNerve Quarterly Sales '23 to '26





ReNerve^{LTD}

Commercial Business

Target Market

ReNerve^{LTD}

The Global Nerve Repair Biomaterials Market is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD\$6.19Bn.

Our Target Markets




Global Nerve Repair Biomaterial Market



Dermal and Amniotic Tissue Surgical Applications (Trauma, plastic surgery)




Dermal and Amniotic Tissue Orthopedics (Tendon and Ligament)




MarketWide Research – Dermal and Amniotic tissue market report 2025-2032, Published 2025.

Global Nerve Repair Biomaterial Market



Global Market by Segment



USD\$1.69Bn

The Global Nerve Repair Biomaterials Market was valued at USD\$1.69Bn in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 17.8% from 2024 to 2031 to USD\$6.19Bn.*



~900k

Nerve surgeries occur in the United States (US) per annum, with no more than 24% of nerve surgeries restoring to 'as good as it was'.



Nerve Compression

Approximately 1-in-4 nerve repair cases receive surgery repair, with 30% failure/revision rates.

* Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

Sales and Marketing Update



Robust Portfolio

25 distributors
In the US

2 direct
salespeople

- Ongoing new approvals
- All approvals designed to add additional SKUs
- All call points use all ReNerve products

Focus surgical areas

Subspecialties



Hand
(upper extremity)



Breast



Lower Extremity
(M.D. & DPM)



Plastics
Reconstruction



Head & Neck



Spine

India

- Significant opportunity
- Existing distribution partner in place
- Surgeon and hospital engagement already underway

Malaysia

- Clear target customer group
- Have gained initial hospital approvals
- Use as a regional distribution hub

Indonesia

- Have initiated surgeon engagement
- In discussion with local distribution partners
- Focus on private hospital systems
- Strong initial interest

Hong Kong


- Strong local partner
- Had initial orders and sales last quarter
- Now engaging with the local market


Philippines

- Complements rest of Asia strategy
- Will focus on key private hospital systems

Thailand

- Focus on private hospitals
- Looking to partner with local distributors





NervAlign®

Nerve Cuff

ReNerve^{LTD}



Key Features

1 Product

- Protects nerves during recovery post peripheral nerve repair
- Great handling characteristics and absorbed within 6 months


2 Patient Benefit

- Bio-absorbed within 6-months.
- Produced using a non-toxic method.
- Terminally sterilised with no residual chemicals.
- Covered under procedural reimbursement rather than individual product reimbursement.
- Promotes revascularisation and remodelling
- Semi-translucent

3 Surgeon Benefit

- Requires no change to surgical technique or procedures.
- Available in various sizes with ability to be trimmed to required shape.
- Is pliable and conforms, semi-translucent and easy to use

Cuff



ReNerve's "Align" Clinical Study

Patient Results

- Definitive clinical study on using NervAlign Nerve Cuff for nerve repair
- 120 patients per cohort
- Comparing standard of care vs treatment with NervAlign Nerve Cuff

Clinical Use

- Hundreds of patients implanted to date
- Received positive feedback from surgeons stating it handles well, is pliable and conforms and has resulted in strong patient outcomes.
- Positive surgeon feedback when used with attachment methods including sutures, glue, micro clips and 'nothing'.

The “Align” Study

Undertaking a definitive study in nerve repair following surgical neurolysis to show the benefit of protecting the nerve post nerve repair surgery.

Study Design: Two patient cohorts

- Control Group: Standard neurectomy repair
- Test Group: Neurectomy repair with NervAlign™ Nerve Cuff
- Based on the study which showed clear benefit for using the NervAlign™ Nerve Cuff


Key Outcomes:

- Testing for significance in Pain Reduction:
 - Secondary outcomes in patient recovery
 - Product performance in surgery
- Patient follow up around 6 to 9 months

Data presentation

- Recruiting the final patients into the study
- Data accumulated along the way
- Data likely to be published and presented in late 2026/early 2027

Comparison of Patient Pre & Post Surgery Pain Score



The comparison of pain scores between the two cohorts of patients



Product Range



Empliq Product Portfolio



	Empliq AmnioLite	Empliq AmnioDuo	Empliq Placental	Empliq Dermal
Description	Single-layer amniotic membrane allograft	Double-layer amniotic membrane allograft	Placental allograft including amniotic membrane and chorion	Deep-layer dermal matrix
Clinical Value	Natural barrier to protect wounds from external environment	Thicker barrier for complex wounds Improved handling characteristics	Natural barrier to protect wounds from external environment Additional structural support	Natural scaffold for protection, reinforcement and capillary formation No basement membrane - rapid tissue ingrowth and healing
Potential Applications	DFUs, VLU, surgical wounds, vulnerable tissue	DFUs, VLU, pressure injury, surgical wounds		Breast reconstruction, Tendon augmentation, abdominal wall repair, hernia repair


ReNerve^{LTD}

Development Programs

Product Development Pipeline


Nerve conduit range

- Nerve Conduit and protector ranges
 - Includes the Nerve cap
 - Significant scale manufacturing ongoing
 - 3 types of conduits to come to market



Nerve guide matrix

- In the commercial development Stage 3 of 4
- FDA approval pathway confirmed
- Next step GMP, commercial manufacturing
- Strong preclinical data out to 12-month implants



ReNerve^{LTD}

R&D Programs

Exploratory Enhancement of Nerve Growth



Collaboration with RMIT with
AEA grant funding




Partners include: Urologist and Colorectal Surgeon

Research Context

- PRPs have been widely used “clinically” including as Injections (e.g. in carpal tunnel – offers benefits over steroids) and intraoperatively.
- Consistency in PRP is key – improve via prep. and characterisation

Preparation of platelet-rich plasma (PRP)



Experimental Approach

- Isolated Platelet Rich Plasma will be added to nerve cuff (directly or via hydrogel matrix)
- PRP Nerve Cuff wrapped around crushed/injured nerve, mimicking damaged to the prostatic nerve plexus (primarily crush, stretch, heat)
- Exploring the repair and response to the damaged nerves

Potential Regenerative Effects

- Evidence suggests PRPs can offer improvements as they contain growth factors eg HGF and IGF-1 and cytokines essential for tissue repair and regeneration.
- PRPs can promote SC proliferation, axonal sprouting, remyelination, and alleviate neuropathic pain through modulation of inflammatory pathways and pain signalling mechanisms
- Additionally, PRP can promote the production of structural / scaffold molecules, including fibronectin, collagen, and hyaluronic acid.

Exploratory Enhancement of Nerve Growth

Exosomes



Partnership with Vivazome

Research Context

- Exosomes are membrane-bound vesicles released by cells including stem cells
- Exosomes carry reparative molecules (eg mRNA's, growth factors)
- Exosomes impact behaviour of other cells, including having anti-fibrotic and anti-inflammatory properties.


Experimental Approach

ReNerve has a collaboration with Vivazome to determine whether the addition of specific exosomes to nerve repair scaffolds will improve their efficacy.

Vivazome have developed purification processes for consistent exosome production.

Method: Load exosomes into cuff/ conduit. Collagen can bind particles, develop loading and release

- Looking for improved and/or accelerated nerve repair and recovery



Value Drivers for the next **12 to 36** **Months**

**2026 to 2029 all about new
products to market and
driving sales**



Building out the product portfolio

- No expansion of the Empliq range required
- All R&D focused on nerve repair products
- A full portfolio competes with the USD\$230M+ revenue a year of AxoGen

Big jumps in sales and revenue

Two main drivers:

- Empliq – will drive rapid sales growth
- New products to expand nerve product sales 'bundle'

Building direct sales

- Direct sales the most effective in driving growth
- Direct sales are costly, requiring balance between investment & growth
- Working with distributors to expand market access

Build supporting data and sales support

- ReNerve focusing on investigator studies to reduce cost but still produce outcomes and data
- Growing data around the benefit of the ReNerve products

Company Portfolio 2029 – with R&D ongoing

ReNerve^{LTD}



ReNerve Milestones



Continued focus on sales expansion with first direct sales reps now full-time



Nerve conduits, nerve guide matrix, nerve caps, nerves stimulators



Building a portfolio of offerings into the market to expand revenue streams and able to 'bundle' into hospitals



Using new markets to expand revenue and support US revenue growth



High margin products allows a pathway to a profitable business

Contact Us

ReNerve Limited

 +61 (03) 9482 3940

 info@renerve.com.au

 Level 10/99 Queen St, Melbourne, Victoria 3000 Australia

Follow us on socials!

